Experimental combo targets Hard-to-Treat cancers in early safety trial
NCT ID NCT02617277
First seen Nov 17, 2025 · Last updated May 23, 2026 · Updated 23 times
Summary
This early-phase study tested the safety of combining two experimental drugs (AZD1775 and durvalumab) in 56 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to identify side effects and determine safe dosing. This trial did not aim to cure the disease, but to gather information for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOURS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Denver, Colorado, 80218, United States
-
Research Site
Sarasota, Florida, 34232, United States
-
Research Site
Nashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.